- Home
- FGI vs BIAF Comparison
FGI vs BIAF Comparison
Compare FGI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- BIAF
- Stock Information
- Founded
- FGI 1987
- BIAF 2014
- Country
- FGI United States
- BIAF United States
- Employees
- FGI N/A
- BIAF 57
- Industry
- FGI Industrial Specialties
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FGI Industrials
- BIAF Health Care
- Exchange
- FGI Nasdaq
- BIAF Nasdaq
- Market Cap
- FGI 7.9M
- BIAF 13.0M
- IPO Year
- FGI 2022
- BIAF 2022
- Fundamental
- Price
- FGI $6.72
- BIAF $2.86
- Analyst Decision
- FGI
- BIAF Hold
- Analyst Count
- FGI 0
- BIAF 1
- Target Price
- FGI N/A
- BIAF N/A
- AVG Volume (30 Days)
- FGI 835.5K
- BIAF 8.5M
- Earning Date
- FGI 11-10-2025
- BIAF 11-13-2025
- Dividend Yield
- FGI N/A
- BIAF N/A
- EPS Growth
- FGI N/A
- BIAF N/A
- EPS
- FGI N/A
- BIAF N/A
- Revenue
- FGI $135,904,413.00
- BIAF $7,681,059.00
- Revenue This Year
- FGI $5.57
- BIAF N/A
- Revenue Next Year
- FGI $8.02
- BIAF $20.04
- P/E Ratio
- FGI N/A
- BIAF N/A
- Revenue Growth
- FGI 12.30
- BIAF 4.99
- 52 Week Low
- FGI $2.28
- BIAF $2.34
- 52 Week High
- FGI $12.62
- BIAF $48.08
- Technical
- Relative Strength Index (RSI)
- FGI 58.14
- BIAF 49.44
- Support Level
- FGI $4.65
- BIAF $2.55
- Resistance Level
- FGI $6.85
- BIAF $3.50
- Average True Range (ATR)
- FGI 0.53
- BIAF 0.33
- MACD
- FGI -0.04
- BIAF -0.10
- Stochastic Oscillator
- FGI 88.18
- BIAF 37.21
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.